Vera Therapeutics Statistics
Share Statistics
Vera Therapeutics has 63.32M shares outstanding. The number of shares has increased by 15.31% in one year.
| Shares Outstanding | 63.32M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 15.49% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 48.99M |
| Failed to Deliver (FTD) Shares | 55.11K |
| FTD / Avg. Volume | 7.48% |
Short Selling Information
The latest short interest is 6.80M, so 10.74% of the outstanding shares have been sold short.
| Short Interest | 6.80M |
| Short % of Shares Out | 10.74% |
| Short % of Float | 13.88% |
| Short Ratio (days to cover) | 12.92 |
Valuation Ratios
The PE ratio is -6.84 and the forward PE ratio is -16.45.
| PE Ratio | -6.84 |
| Forward PE | -16.45 |
| PS Ratio | 352.76 |
| Forward PS | 54 |
| PB Ratio | 6.46 |
| P/FCF Ratio | -7.12 |
| PEG Ratio | n/a |
Enterprise Valuation
Vera Therapeutics Inc. has an Enterprise Value (EV) of 664.86M.
| EV / Earnings | -6.93 |
| EV / Sales | 357.07 |
| EV / EBITDA | -6.52 |
| EV / EBIT | -6.52 |
| EV / FCF | -7.21 |
Financial Position
The company has a current ratio of 7.71, with a Debt / Equity ratio of 0.49.
| Current Ratio | 7.71 |
| Quick Ratio | 7.71 |
| Debt / Equity | 0.49 |
| Total Debt / Capitalization | 32.91 |
| Cash Flow / Debt | -1.85 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.94% and return on capital (ROIC) is -65.65%.
| Return on Equity (ROE) | -0.94% |
| Return on Assets (ROA) | -0.55% |
| Return on Capital (ROIC) | -65.65% |
| Revenue Per Employee | 22.71K |
| Profits Per Employee | -1.17M |
| Employee Count | 82 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 1K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 177.85% in the last 52 weeks. The beta is 1.02, so Vera Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.02 |
| 52-Week Price Change | 177.85% |
| 50-Day Moving Average | 45.35 |
| 200-Day Moving Average | 40.73 |
| Relative Strength Index (RSI) | 45.79 |
| Average Volume (20 Days) | 737.13K |
Income Statement
In the last 12 months, Vera Therapeutics had revenue of 1.86M and earned -95.99M in profits. Earnings per share was -2.25.
| Revenue | 1.86M |
| Gross Profit | 1.86M |
| Operating Income | -102.01M |
| Net Income | -95.99M |
| EBITDA | -102.01M |
| EBIT | -102.01M |
| Earnings Per Share (EPS) | -2.25 |
Balance Sheet
The company has 45.68M in cash and 53.71M in debt, giving a net cash position of -8.03M.
| Cash & Cash Equivalents | 45.68M |
| Total Debt | 53.71M |
| Net Cash | -8.03M |
| Retained Earnings | -309.10M |
| Total Assets | 368.56M |
| Working Capital | 337.67M |
Cash Flow
In the last 12 months, operating cash flow was -92.18M and capital expenditures -63.00K, giving a free cash flow of -92.24M.
| Operating Cash Flow | -92.18M |
| Capital Expenditures | -63.00K |
| Free Cash Flow | -92.24M |
| FCF Per Share | -2.16 |
Margins
Gross margin is 10.00K%, with operating and profit margins of -547.86K% and -515.52K%.
| Gross Margin | 10.00K% |
| Operating Margin | -547.86K% |
| Pretax Margin | -515.52K% |
| Profit Margin | -515.52K% |
| EBITDA Margin | -5.48K% |
| EBIT Margin | -5.48K% |
| FCF Margin | -4.95K% |
Dividends & Yields
VERA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -5.21% |
| FCF Yield | -3.38% |
Analyst Forecast
The average price target for VERA is $66, which is 53% higher than the current price. The consensus rating is "Buy".
| Price Target | $66 |
| Price Target Difference | 53% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Scores
| Altman Z-Score | 18.37 |
| Piotroski F-Score | 2 |